Gyre Therapeutics Inc

Gyre Therapeutics’ CEO Luo Ying’s recent insider sales signal strategic capital re‑allocation, not distress, amid a preferred‑stock merger and R&D push for metabolic therapies.

Gyre Therapeutics insider buying signals CEO confidence in its hydronidone pipeline—potential upside awaits next trial data release.